IDO inhibitors
AssigneeNewLink Genetics Corporation
InventorsMario Mautino, Sanjeev Kumar, Jesse Waldo, Firoz Jaipuri, Tanay Kesharwani, Xiaoxia Zhang
Life of this patent
Estimating the term…
Abstract
Presently provided are IDO inhibitors and pharmaceutical compositions thereof, useful for modulating an activity of indoleamine 2,3-dioxygenase; treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression; treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; treating tumor-specific immunosuppression associated with cancer; and treating immunosuppression associated with an infectious disease.
Claims36
A compound of the formula,
- or a pharmaceutically acceptable salt thereof, wherein
- bond α is a single bond;
- n is 0, 1 or 2;
- each R1 is independently fluoro, chloro, hydroxy, or methoxy;
- R2 is —CH2—RA—, wherein
- RA is —CN, —C(O)R3, —C(O)OR3, —C(O)N(R3)(RC),
- —C(ORB)(R3)(RC), —C(NHRB)(R3)(RC), or —C(═N—ORC)R3, wherein
- RB is hydrogen or C1-6alkyl;
- R3 is
- wherein
- bond a is a single bond or a double bond;
- m is 0, 1, or 2;
- p is 0 or 1;
- and wherein
- when bond a is a single bond, then Z is —C(R36)2—, —C(═R32)—, —N(R35)—, or —O—, wherein
- R35 is hydrogen, C1-6alkyl, —C(O)R, —S(O)2R, —C(O)OR, —C(O)N(R)2, —S(O)2OR, or —S(O)2N(R)2;
- and when bond a is a double bond, then Z is —C(R36)═ or —N═;
- each R36 is independently hydrogen or R31;
- R32 is ═O, ═S, ═N(R), ═N(OR), ═C(R34)2, =(spiro-C3-8cycloalkyl), or =(spiro-(3-10 membered heterocyclyl)), wherein
- each R34 is independently hydrogen, halogen, C1-6alkyl, C1-6haloalkyl, C3-8cycloalkyl, or 3-10 membered heterocyclyl;
- or both R34 taken together with the atom to which they are both attached form a monocyclic C3-8cycloalkyl or monocyclic 3-8 membered heterocyclyl;
- each R31 is independently halogen, cyano, nitro, C1-6alkyl, —C1-6alkyl-R33, C1-6haloalkyl, —OR, —N(R)2, —SR, —C(O)OR, —C(O)N(R)2, —C(O)R, —S(O)R, —S(O)OR, —S(O)N(R)2, —S(O)2R, —S(O)2OR, —S(O)2N(R)2, —OC(O)R, —OC(O)OR, —OC(O)N(R)2, —N(R)C(O)R, —N(R)C(O)OR, —N(R)C(O)N(R)2, wherein
- R33 is cyano, —OR, —N(R)2, —SR, —C(O)OR, —C(O)N(R)2, —C(O)R, —S(O)R, —S(O)OR, —S(O)N(R)2, —S(O)2R, —S(O)2OR, —S(O)2N(R)2, —OC(O)R, —OC(O)OR, —OC(O)N(R)2, —N(R)C(O)R, —N(R)C(O)OR, or —N(R)C(O)N(R)2;
- RC is hydrogen or C1-6alkyl;
- and
- each R is independently hydrogen or R10, wherein
- R10 is C1-6alkyl, C1-6haloalkyl, aryl, heteroaryl, C3-8cycloalkyl, C3-8cycloalkenyl, 3-10 membered heterocyclyl, arylC1-6alkyl, heteroarylC1-6alkyl-, C3-8 cycloalkylC1-6alkyl-, C3-8cycloalkenylC1-6alkyl-, or (3-10 membered heterocyclyl)C1-6alkyl-, each R10 optionally substituted by one, two, three, or four groups that are each independently halogen, cyano, nitro, C1-6alkyl, C1-6haloalkyl, —OR11, —N(R11)2, —SR11, —C(O)OR11, —C(O)N(R11)2, —C(O)R11, —S(O)R11, —S(O)OR11, —S(O)N(R11)2, —S(O)2R11, —S(O)2OR11, —S(O)2N(R11)2, —OC(O)R11, —OC(O)OR11, —OC(O)N(R11)2, —N(R11)C(O)R11, —N(R11)C(O)OR11, —N(R11)C(O)N(R11)2, wherein each R11 is independently hydrogen or C1-6alkyl.
Dependencies are inferred from the claim text.